LZYY(SH:603368) Xin Lang Zheng Quan·2025-10-31 14:45Core Viewpoint - Liu Pharmaceutical Group, established in 1981 and listed in 2014, is a leading pharmaceutical distribution company in Guangxi, with a comprehensive business model covering wholesale, retail, and industrial sectors [1] Financial Performance - As of Q3 2025, Liu Pharmaceutical Group reported revenue of 15.758 billion yuan, ranking 11th in the industry, while the net profit was 654 million yuan, ranking 5th [2] - The company's revenue growth has shown stability, with a notable increase in retail income and a focus on differentiated product advantages [5][6] Financial Ratios - The asset-liability ratio for Liu Pharmaceutical Group in Q3 2025 was 61.59%, higher than the industry average of 59.74% [3] - The gross profit margin was 10.88%, which is below the industry average of 13.11% [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 7.62%, while the average number of circulating A-shares held per shareholder increased by 8.25% [5] - Major shareholders include Hong Kong Central Clearing Limited and Southern CSI 1000 ETF, with changes in their holdings noted [5] Management Compensation - The chairman, Zhu Chaoyang, received a salary of 956,400 yuan in 2024, an increase of 17,500 yuan from the previous year [4] Future Outlook - Forecasts for 2025-2027 predict revenues of 21.133 billion, 22.221 billion, and 23.383 billion yuan, with corresponding net profits of 828 million, 873 million, and 922 million yuan [6]